A new antibiotic has been approved by the U.S. Food and Drug Administration (FDA) to treat three different infections, giving health care providers a new tool in their toolkit.
Zevtera received approval on Wednesday for treating adults with Staphylococcus aureus (S. aureus) bloodstream infections, including those with right-sided infective endocarditis; adults with acute bacterial skin and skin structure infections; and adults and children with community-acquired bacterial pneumonia. The antibiotic is manufactured by Swiss pharmaceutical company Basilea Pharmaceutica.
